Multicenter, Randomized, Open-label, Parallel-group Study to Evaluate User Satisfaction With and Tolerability of the Low-dose Levonorgestrel (LNG) Intrauterine Delivery System (IUS) With 12 microg LNG/Day Initial in Vitro Release Rate (LCS12) in Comparison to a Combined Oral Contraceptive Containing 30 microg Ethinyl Estradiol and 3 mg Drospirenone (Yasmin) in Young Women (18-29 Years) Over 18 Months of Use.
Phase of Trial: Phase III
Latest Information Update: 31 Jan 2017
At a glance
- Drugs Levonorgestrel (Primary) ; Drospirenone/ethinylestradiol
- Indications Pregnancy
- Focus Therapeutic Use
- Sponsors Bayer
- 15 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 24 Apr 2012 Planned end date changed from 1 Jul 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.
- 22 Jun 2011 Planned end date changed from 1 Feb 2013 to 1 Jul 2014 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History